Release of neuron-specific enolase and S100 after implantation of cardioverters/defibrillators

Crit Care Med. 2003 Aug;31(8):2085-9. doi: 10.1097/01.CCM.0000079610.88771.62.

Abstract

Objective: Repeated induction of ventricular fibrillation with ensuing alterations in electroencephalogram and jugular venous oxygen saturation is common practice during insertion of transvenous implantable cardioverters/defibrillators. We investigated whether these functional changes are also associated with cerebral injury.

Design: Prospective study.

Setting: University hospital.

Patients: We studied 45 patients undergoing implantable cardioverter/defibrillator insertion. Eleven patients with cardiac pacemaker implantation, which was performed in the same manner yet without the necessity to induce ventricular fibrillation, served as controls.

Measurements and main results: Serum neuron-specific enolase and S100 were determined before, immediately postoperatively, and 2 hrs postoperatively. In a randomly composed subgroup, neuron-specific enolase was also determined 6 and 24 hrs after surgery. Implantable cardioverter/defibrillator patients only showed an increase of both markers postoperatively. Median neuron-specific enolase values climbed from a preoperative 9.9 to 12.3 and 14.4 microg/L at 2 and 24 hrs after surgery, respectively. This increase was associated with the number of shocks and the cumulative time in circulatory arrest. The highest median S100 level (0.075 microg/L) was reached 2 hrs after the procedure. Neuron-specific enolase and S100 were extremely elevated (13.7 and 0.970 microg/L, respectively) in one patient after an extended episode of ventricular fibrillation. Plasma hemoglobin levels were in the normal range in implantable cardioverter/defibrillator patients throughout the observation period.

Conclusions: Apparently, even brief successive periods of global cerebral ischemia cause neuronal damage without obvious severe neurologic deficits. However, they may be related to subtle postoperative neurologic or cognitive dysfunctions that a number of implantable cardioverter/defibrillator patients exhibit after implantation.

MeSH terms

  • Aged
  • Brain Ischemia / blood
  • Brain Ischemia / etiology*
  • Cerebrovascular Circulation
  • Defibrillators, Implantable / adverse effects*
  • Female
  • Heart Arrest, Induced / adverse effects*
  • Humans
  • Male
  • Monitoring, Intraoperative
  • Phosphopyruvate Hydratase / blood*
  • Postoperative Period
  • Prospective Studies
  • S100 Proteins / blood*
  • Tachycardia, Ventricular / therapy

Substances

  • S100 Proteins
  • Phosphopyruvate Hydratase